COMMUNIQUÉS West-GlobeNewswire

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2018

03/08/2018 - 12:00

RANCHO CUCAMONGA, Calif., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2018 ended June 30, 2018, after the [...]

HMS Holdings Corp. Reports Second Quarter 2018 Results

03/08/2018 - 12:00

Total Q2 Revenue of $146.8 Million / YTD Total Revenue Up 13% Excluding Q1 Reserve Release Record Quarterly Commercial Revenue of $80.5 Million in Q2 – Up 16% Compared to Q2’17 Full-Year 2018 Outlook Raised - Including [...]

Athersys Makes Important Leadership Hire to Carry Out Its Manufacturing Strategy

03/08/2018 - 12:00

Company Appoints Greg Liposky, MBA as Senior Vice President of Commercial Manufacturing CLEVELAND, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced the addition of an experienced manufacturing [...]

William Demant: Investor news - William Demant and Philips partner in hearing healthcare

03/08/2018 - 08:01

Investor news 3 August 2018 William Demant and Philips partner in hearing healthcare Based on a shared vision of improving the lives of people through innovative healthcare, William Demant will bring Philips-branded [...]

Shire plc : Rule 2.9 Announcement

03/08/2018 - 08:01

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 3 August 2018 [...]

Fagron realised organic turnover growth of 8.5%

03/08/2018 - 07:02

Regulated information | Consolidated results for the first semester of 2018 Nazareth (Belgium)/Rotterdam (the Netherlands), 3 August 2018 Fagron realised organic turnover growth of 8.5% Organic turnover growth in all [...]

HitGen Launching Initiative to Discover New Medicines to Combat Tuberculosis and Malaria

03/08/2018 - 02:00

Grant Funding provided by the Bill & Melinda Gates Foundation to Use HitGen’s DNA-Encoded Library Technology CHENGDU, China, Aug. 03, 2018 (GLOBE NEWSWIRE) -- HitGen Ltd., a privately held biotech company, announced [...]

Idera Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

02/08/2018 - 22:30

Abstract accepted for 2018 European Society of Medical Oncology Annual Meeting Cash runway into first quarter of 2020 EXTON, Pa., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a [...]

Profound Medical to Release Second Quarter 2018 Financial Results on August 14 – Conference Call to Follow

02/08/2018 - 22:30

TORONTO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time [...]

Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months of 2018

02/08/2018 - 22:30

Q2 2018 total revenues of $220 million, net income of $50 million Reaffirms full year 2018 financial forecast and operational goals GAITHERSBURG, Md., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: [...]

The Ensign Group Reports Second Quarter Results

02/08/2018 - 22:20

Conference Call and Webcast scheduled for tomorrow, August 3, 2018 at 10:00 am PT MISSION VIEJO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq:ENSG), the parent company of the Ensign™ group of [...]

Alpha Pro Tech, Ltd. Announces Financial Results for the Second Quarter Ended June 30, 2018

02/08/2018 - 22:15

Revenue for the second quarter of 2018 increased 7.3% to $12.1 million, compared to $11.3 million for the second quarter of 2017 Net income for the second quarter of 2018 was $959,000, or $0.07 per diluted share, [...]

Corvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

02/08/2018 - 22:15

BURLINGAME, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted [...]

Tetraphase Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights

02/08/2018 - 22:10

WATERTOWN, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening [...]

Alphatec Reports Second Quarter 2018 Financial Results

02/08/2018 - 22:05

CARLSBAD, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a provider of innovative spine surgery solutions with a mission to improve patient lives through the [...]

IRIDEX Announces 2018 Second Quarter Results and Raises Full Year 2018 Guidance

02/08/2018 - 22:05

MOUNTAIN VIEW, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended June 30, 2018. Second Quarter Highlights Cyclo G6™ [...]

Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2018 Financial Results on Wednesday, August 8, 2018

02/08/2018 - 22:05

BOSTON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will [...]

Marrone Bio Innovations Appoints Large Growers, Keith McGovern and Stuart Woolf, to Board of Directors

02/08/2018 - 22:05

Company Forms Advisory Council to Advise the Board and Management’s Strategic Vision for the Company DAVIS, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (MBI) (NASDAQ: MBII), a leading [...]

TESARO Announces Second-Quarter 2018 Operating Results

02/08/2018 - 22:05

ZEJULA ® Q2 net sales totaled $54 million compared to $26 million for Q2 2017 QUADRA sNDA submission planned for Q4 2018 PRIMA Phase 3 ZEJULA monotherapy trial in first-line ovarian cancer regardless of biomarker status [...]